Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

Trading update for 2005-2006 financial year

Abcam today provided a trading update for the year ending 30 June 2006 ahead of its preliminary results, which are expected to be announced in early September 2006.

At the time of the Company's admission to AIM in November 2005 the Directors stated that they expected the Company to achieve sales of no less than £18.5 million for the year ending 30 June 2006. In the period since the Company's interim results were announced on 14 February 2006 trading has been strong, particularly in the US. Consequently, the Directors now expect sales for the year ending 30 June 2006 to be approximately £19.4 million (2005: £12.1 million).

Given this strong sales performance and the Company's continued focus on margin control, the Directors expect pre-tax profits for the year ending 30 June 2006, subject to any unforeseen audit adjustments, to be ahead of market expectations.

Also, the Company has incorporated a subsidiary in Japan to enable it to begin to promote the sale of its products effectively in that market.

Jonathan Milner, Abcam's Chief Executive Officer, said: "We are pleased with the continued strong performance at Abcam but recognise that we operate in a competitive market. We continue to invest in new products, improved systems and international expansion, particularly in the Japanese market."

---

back to news list